Artiva Biotherapeutics, Inc.(ARTV)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $33.5M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ARTV Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Artiva Biotherapeutics, Inc. (ARTV), a Healthcare sector company. ARTV is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $33.5m in revenue. Based on the latest XBRL financial filings (Q1 2026), Artiva Biotherapeutics, Inc. reports net income of $-23.5M, free cash flow of $-21.2M. Top institutional holders of ARTV by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., 5AM Venture Management,, VR Adviser,, based on the most recent SEC filings. ARTV trades on the Nasdaq exchange and files with the SEC under CIK 1817241. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARTV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Artiva Biotherapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-23.5M
Free Cash Flow
Q1 2026
$-21.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-100.0% YoYNet Income
-28.3% YoYOperating Income
-33.5% YoYEPS (Diluted)
+41.0% YoYTotal Assets
-37.5% YoYOp. Cash Flow
-39.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $0.00 -100.0% | $251.0K -99.3% | $33.5M |
| Net Income | $-83.9M -28.3% | $-65.4M -127.6% | $-28.7M |
| Operating Income | $-89.8M -33.5% | $-67.3M -119.4% | $-30.7M |
| EPS (Diluted) | $-3.43 +41.0% | $-5.81 +83.8% | $-35.78 |
| Total Assets | $130.9M -37.5% | $209.6M +99.4% | $105.1M |
| Operating Cash Flow | $-76.8M -39.5% | $-55.0M -16.0% | $-47.4M |
AI Insight: ARTV Ratio Trends
Return metrics have deteriorated sharply every quarter since Q3 2024, with ROE reaching -107.1% in Q1 2026 — consistent with a pre-revenue clinical-stage cash burn profile.
• ROE worsened from -34.8% in Q3 2024 to -107.1% in Q1 2026, a deterioration of over 72 percentage points across six quarters.
• ROA followed the same trajectory, declining from -31.0% in Q3 2024 to -88.8% in Q1 2026, reflecting deepening asset-level losses.
• ROIC fell from -36.5% in Q3 2024 to -79.8% in Q4 2025, the last quarter with available data — more than doubling in magnitude.
⚠ Operating margin and net profit margin are unavailable across all periods, severely limiting visibility into cost structure and revenue progress.
⚠ Accelerating ROE deterioration (-75.6% in Q4 2025 to -107.1% in Q1 2026) may signal faster cash consumption; runway duration is a key watch.
Get alerted when ARTV's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Artiva Biotherapeutics, Inc. including:
Top Institutional Holders of ARTV
RA CAPITAL MANAGEMENT, L.P.
$63.5M9,853,302 sh5AM Venture Management, LLC
$15.2M2,353,304 shVR Adviser, LLC
$10.4M1,609,569 shvenBio Partners LLC
$3.4M531,337 shFRANKLIN RESOURCES INC
$3.4M520,327 shRevelation Capital Management, LLC
$1.9M299,311 shBlackRock, Inc.
$1.4M213,388 shVANGUARD CAPITAL MANAGEMENT LLC
$1.3M207,686 shWELLINGTON MANAGEMENT GROUP LLP
$1.3M194,108 shPropel Bio Management, LLC
$949.8K146,369 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $63.5M | 9,853,302 |
| 5AM Venture Management, LLC | $15.2M | 2,353,304 |
| VR Adviser, LLC | $10.4M | 1,609,569 |
| venBio Partners LLC | $3.4M | 531,337 |
| FRANKLIN RESOURCES INC | $3.4M | 520,327 |
| Revelation Capital Management, LLC | $1.9M | 299,311 |
| BlackRock, Inc. | $1.4M | 213,388 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.3M | 207,686 |
| WELLINGTON MANAGEMENT GROUP LLP | $1.3M | 194,108 |
| Propel Bio Management, LLC | $949.8K | 146,369 |
More Healthcare Companies
View all Healthcare →Put ARTV on your watchlist
Track score changes the day Artiva Biotherapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ARTV a good stock to buy?
13F Pro's AI-powered analysis of Artiva Biotherapeutics, Inc. (ARTV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ARTV are available on the ARTV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ARTV?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ARTV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Artiva Biotherapeutics, Inc.'s investment landscape.